“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy

“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy

BackgroundThe first-in-class approved BCMA CAR-T therapy was idecabtagene vicleucel (ide-cel), approved in March 2021, for RRMM patients who progressed after 4 or more lines of therapy. Despite the promising outcomes, there were limited apheresis/production slots for ide-cel. We report outcomes of p...

Full description

Bibliographic Details
Main Authors: Nausheen Ahmed, William Wesson, Muhammad Umair Mushtaq, Rajat Bansal, Haitham AbdelHakim, Sarah Bromert, Allison Appenfeller, Batool Abu Ghazal, Anurag Singh, Sunil Abhyankar, Siddhartha Ganguly, Joseph McGuirk, Al-Ola Abdallah, Leyla Shune
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Oncology
Subjects:
BCMA
ide-cel
access
production slot
waitlist
myeloma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1206715/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1206715/full

Similar Items